Chairs: John Wilding (GBR), Xavier Cos (ESP)
| 17:00 – 17:02 | Introduction | John Wilding (GBR) |
| 17:02 – 17:10 | Early glycemic control with SGLT2 inhibitors and its long-lasting benefits | John Wilding (GBR) |
| 17:10 – 17:18 | Blunting the progression of kidney disease with Canagliflozin in patients with T2D: How, when and who? | Hiddo L. Heerspink (NLD) |
| 17:18 – 17:26 | Getting to the heart of the matter: Canagliflozin cardiovascular benefits in T2D | David Matthews (GBR) |
| 17:26 – 17:34 | Cardio-renal-metabolic care in T2D: be holistic! | Apostolos Tsapas (GRC)* |
| 17:34 – 17:38 | Round table introduction | Xavier Cos (ESP) |
| 17:38 – 17:58 | Round table: addressing barriers for early initiation of the therapy | All faculty |
| 17:58 – 18:00 | Wrap-up and takeaway messages | John Wilding (GBR) |
*Independent comment and pro-bono participation
- Monday, 9 September 2024
- 17:00 - 18:00 CEST
- Vienna Hall
